capacity, consent and conflicts of interest: * the person lacks capacity; * the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; * the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. * unable to complete the daily symptom tracker * unable to communicate in english or welsh comorbidities: * known hypersensitivity or allergy to any component of the test product; * severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; * severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; * a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms or spray administration; * an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: * participants with proven covid-19 infection (previous positive serology and/or viral pcr swab) * participants that have already received their vaccination or already booked in for their vaccination medications: * recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) * participants taking any of the medications outlined in table 2 during the trial period will be excluded

capacity, consent and conflicts of interest: * the person lacks capacity; * the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; * the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. * unable to complete the daily symptom tracker * unable to communicate in english or welsh comorbidities: * known hypersensitivity or allergy to any component of the test product; * severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; * severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; * a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms or spray administration; * an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: * participants with proven covid-19 infection (previous positive serology and/or viral pcr swab) * participants that have already received their vaccination or already booked in for their vaccination medications: * recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) * participants taking any of the medications outlined in table 2 during the trial period will be excluded

capacity, consent and conflicts of interest: - the person lacks capacity; - the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; - the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. - unable to complete the daily symptom tracker - unable to communicate in english or welsh comorbidities: - known hypersensitivity or allergy to any component of the test product; - severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; - severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; - a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms or spray administration; - an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: - participants with proven covid-19 infection (previous positive serology and/or viral pcr swab) - participants that have already received their vaccination or already booked in for their vaccination medications: - recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) - participants taking any of the medications outlined in table 2 during the trial period will be excluded

capacity, consent and conflicts of interest: - the person lacks capacity; - the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; - the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. - unable to complete the daily symptom tracker - unable to communicate in english or welsh comorbidities: - known hypersensitivity or allergy to any component of the test product; - severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; - severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; - a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms or spray administration; - an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: - participants with proven covid-19 infection (previous positive serology and/or viral pcr swab) - participants that have already received their vaccination or already booked in for their vaccination medications: - recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) - participants taking any of the medications outlined in table 2 during the trial period will be excluded

capacity, consent and conflicts of interest: - the person lacks capacity; - the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; - the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. - unable to complete the daily symptom tracker - unable to communicate in english or welsh comorbidities: - known hypersensitivity or allergy to any component of the test product; - severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; - proven hypersensitivity of allergy resulting in hay fever and rhinitis; - severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; - a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms; - an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: - participants with proven covid-19 infection (positive serology and/or viral pcr swab) medications: - recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) - participants taking any of the medications outlined in table 2 during the trial period will be excluded

capacity, consent and conflicts of interest: - the person lacks capacity; - the subject is related to any study personnel or has any other close ties or conflicts of interest with the research team or the study sponsor; - the subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study. - unable to complete the daily symptom tracker - unable to communicate in english or welsh comorbidities: - known hypersensitivity or allergy to any component of the test product; - severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease, immune deficiency, autoimmune disease or a history or any current disease that is considered by the investigator as a reason for exclusion; - proven hypersensitivity of allergy resulting in hay fever and rhinitis; - severe nasal septal deviation, nasal polyps or other non-infectious condition that could cause nasal obstruction; - a history of any nasal or sinus surgery in the past that in the opinion of the investigator may influence the symptoms; - an unrelated infection that in the opinion of the investigator may influence symptoms (gastrointestinal infection, other viral diseases such as measles, mumps); covid-19 status: - participants with proven covid-19 infection (positive serology and/or viral pcr swab) medications: - recent treatment of common cold that in the opinion of the investigator may influence symptoms (see table 2) - participants taking any of the medications outlined in table 2 during the trial period will be excluded